| Assessment Status |
Awaiting full HTA submission from Applicant |
| HTA ID |
25013 |
| Drug |
Ravulizumab |
| Brand |
Ultomiris® |
| Indication |
Ravulizumab (Ultomiris®) is indicated for the treatment of adult patients with neuromyelitis optica spectrum disorder who are anti-aquaporin 4 antibody positive. |
| Rapid review commissioned |
17/02/2025 |
| Rapid review completed |
14/03/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ravulizumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
31/03/2025 |
| Pre-submission consultation with Applicant |
26/11/2025 |
